NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
Filed with ASX · · 2 pages · English
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Receipt of Binding Commitments for $4.5m Placement
- Neurotech secures $3.15 million R&D tax incentive loan
- US FDA clears IND for NTI164
- NTI secures Notices of Allowance for US patent applications
- NTI initiates First Clinical Site for Phase 3 ASD Trial
Later from Neurotech International
All Neurotech International news releasesFollow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International